- Trials with a EudraCT protocol (373)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
373 result(s) found for: Wild type.
Displaying page 1 of 19.
EudraCT Number: 2015-001543-36 | Sponsor Protocol Number: 107625 | Start Date*: 2015-06-22 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase III, double-blind, randomised, placebo-controlled, multi-centre study in Japan to assess the efficacy, safety, reactogenicity and immunogenicity of the lyophilised formulation of GlaxoSmith... | ||
Medical condition: Healthy volunteers | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2015-001485-26 | Sponsor Protocol Number: 102248,111274 | Start Date*: 2015-06-22 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase III, double-blind, randomised, placebo-controlled, multi-center study to assess the efficacy, safety and immunogenicity of two or three doses of GSK Biologicals’ oral live attenuated human ... | ||
Medical condition: Healthy volunteers | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2015-001541-92 | Sponsor Protocol Number: 444563/028/029/030,107070,72,76 | Start Date*: 2015-06-11 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals’ oral live attenuated human rotavir... | ||
Medical condition: Healthy volunteers (Active immunisation of infants against gastroenteritis (GE) due to rotavirus (RV).) | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-000349-59 | Sponsor Protocol Number: 0244190615-02 | Start Date*: 2014-05-12 |
Sponsor Name:department of experimental and clinical medicine "F. Magrassi" | ||
Full Title: METAL (METformin in Advanced Lung cancer) study: PHASE II STUDY OF METFORMIN PLUS ERLOTINIB IN SECOND LINE THERAPY OF STAGE IV NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS | ||
Medical condition: Patients with metastatic non small cell lung cancer in second line therapy | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-022951-49 | Sponsor Protocol Number: 20100007 | Start Date*: 2011-06-06 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Open-label Trial to Evaluate the Survival Benefit of Panitumumab and Best Supportive Care, Compared to Best Supportive Care Alone, in Subjects With Chemorefracto... | |||||||||||||
Medical condition: Chemorefractory, Wild-type Kirsten rat sarcoma viral oncogene homolog (KRAS), Metastatic Colorectal Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) EE (Completed) LV (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002871-15 | Sponsor Protocol Number: V58P13 | Start Date*: 2007-09-14 |
Sponsor Name:Novartis Vaccines and Diagnostics S.r.l. | ||
Full Title: A Phase III, Randomized, Observer-Blind, Placebo-Controlled, Multicenter Study to Assess Clinical Efficacy of a Cell-Derived Subunit Influenza Vaccine and an Egg-Derived Subunit Influenza Vaccine i... | ||
Medical condition: Influenza disease. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-014041-81 | Sponsor Protocol Number: 2906 | Start Date*: 2009-11-13 |
Sponsor Name:GOIM GRUPPO ONCOLOGICO MERIDIONALE | ||
Full Title: Optimal strategy in K-ras wild type metastatic colorectal cancer patients: cetuximab plus FOLFIRI followed by FOLFOX+/- cetuximab (GOIM multicenter program) | ||
Medical condition: k-ras wild type metastatic colorectal cancer patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004003-39 | Sponsor Protocol Number: 2018-BN-001 | Start Date*: 2018-12-19 | ||||||||||||||||
Sponsor Name:UZ Brussel | ||||||||||||||||||
Full Title: A stratified dual-arm open-label two-stage phase 2 trial of trametinib in patients with advanced pretreated BRAFV600 wild-type melanoma | ||||||||||||||||||
Medical condition: ADVANCED PRETREATED BRAFV600 WILD-TYPE MELANOMA | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003065-15 | Sponsor Protocol Number: WO29519 | Start Date*: 2015-12-15 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE III STUDY OF IDASANUTLIN, AN MDM2 ANTAGONIST, WITH CYTARABINE VERSUS CYTARABINE PLUS PLACEBO IN PATIENTS WITH RELAPSED OR REFRACTO... | |||||||||||||
Medical condition: Relapsed or refractory acute myeloid leukemia (AML). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) FI (Prematurely Ended) GB (Prematurely Ended) NO (Completed) BE (Completed) NL (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-008282-36 | Sponsor Protocol Number: GPICD–CR–0801 | Start Date*: 2010-05-07 |
Sponsor Name:Grupo de Investigação do Cancro Digestivo | ||
Full Title: Randomized, open-label phase II study evaluating the safety and efficacy of Cetuximab plus modified FOLFOX - 6 versus modified FOLFOX - 6 alone as 2nd line therapy after progression on the 1st line... | ||
Medical condition: Colorectal cancer KRAS wild-type | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2009-012655-26 | Sponsor Protocol Number: HE 6A/09 | Start Date*: 2010-07-13 | |||||||||||
Sponsor Name:Hellenic Cooperative Oncology Group | |||||||||||||
Full Title: A SINGLE-ARM, MULTICENTER, PHASE II STUDY OF PANITUMUMAB IN COMBINATION WITH CAPECITABINE / OXALIPLATIN IN FIRST-LINE, WILD-TYPE K-RAS METASTATIC COLORECTAL CANCER PATIENTS | |||||||||||||
Medical condition: Wild-type K-ras metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006552-36 | Sponsor Protocol Number: 109810 | Start Date*: 2007-01-18 |
Sponsor Name:GlaxoSmithKline | ||
Full Title: A phase IIIb open study to assess the long-term efficacy and safety of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine approximately three years after vaccinat... | ||
Medical condition: Long-term efficacy and safety follow-up | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-004593-56 | Sponsor Protocol Number: CAVE-2 | Start Date*: 2022-05-19 | |||||||||||
Sponsor Name:GRUPPO ONCOLOGICO DELL'ITALIA MERIDIONALE | |||||||||||||
Full Title: A phase II randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients | |||||||||||||
Medical condition: Pre-treated RAS/BRAF wild type metastatic colorectal cancer patients. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005605-36 | Sponsor Protocol Number: SCI-Ta1-NSCLC-CHEMOP2-001 | Start Date*: 2016-07-07 | |||||||||||
Sponsor Name:SCICLONE PHARMACEUTICALS ITALY S.R.L. | |||||||||||||
Full Title: Thymosin alpha 1 plus maintenance therapy with the Standard of Care (SoC) chemotherapy plus cisplatin (or carboplatin) in patients with metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR wild type | |||||||||||||
Medical condition: metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR wild type | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001210-15 | Sponsor Protocol Number: MOU-2017-02 | Start Date*: 2018-11-19 |
Sponsor Name:Masarykův onkologický ústav | ||
Full Title: Rational Anti-EGFR therapy Selection for the first-line treatment of patients with metastatic KRAS/NRAS wild type colorectal cancer based on the use of molecular predictor miR-31-5p (RASmiR) | ||
Medical condition: inoperable, untreated, wild type RAS (wt KRAS/wtNRAS), metastatic colorectal cancer (mCRC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2008-004281-71 | Sponsor Protocol Number: 20070509 | Start Date*: 2009-02-10 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously ... | |||||||||||||
Medical condition: Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001540-10 | Sponsor Protocol Number: 444563/024 | Start Date*: 2015-06-11 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase III, double-blind, randomised, placebo-controlled, multi-country and multi-center study to assess the efficacy, immunogenicity and safety of two doses of GSK Biologicals’ oral live attenuat... | ||
Medical condition: Rotavirus gastroenteritis | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2017-003242-25 | Sponsor Protocol Number: GITuD-20172019 | Start Date*: 2018-03-02 | |||||||||||
Sponsor Name:ASOCIACION GITuD | |||||||||||||
Full Title: Analysis of 2nd line panitumumab + FOLFIRI efficacy in wild type RAS converted subjects from initially mutated RAS subjects with metastatic colorectal cancer treated in 1st line with standard FOLFO... | |||||||||||||
Medical condition: Wild-type RAS metastatic colorectal cancer (mCRC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002095-40 | Sponsor Protocol Number: B2151005 | Start Date*: 2014-06-12 | |||||||||||||||||||||
Sponsor Name:Pfizer Inc.,235 East 42nd Street, New York, NY 10017 | |||||||||||||||||||||||
Full Title: A RANDOMIZED PHASE 2 STUDY OF PF-05212384 PLUS IRINOTECAN VERSUS CETUXIMAB PLUS IRINOTECAN IN PATIENTS WITH KRAS AND NRAS WILD TYPE METASTATIC COLORECTAL CANCER | |||||||||||||||||||||||
Medical condition: Colorectal Cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: BE (Completed) IT (Prematurely Ended) ES (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-001175-19 | Sponsor Protocol Number: 102247 | Start Date*: 2004-08-24 |
Sponsor Name:GlaxoSmithKline | ||
Full Title: A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenua... | ||
Medical condition: Two-dose immunization according to 0, 1 or 2-month schedule against rotavirus disease in healthy infants aged 6 to 14 weeks at the time of the first dose. Rotavirus infection. | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: FI (Completed) CZ (Completed) IT (Completed) ES (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
